Behzad Ali, Feldmann-Schulz Christoph, Lenz Bernd, Clarkson Lucy, Ludwig Celine, Luttenberger Katharina, Völkl Simon, Kornhuber Johannes, Mühle Christiane, von Zimmermann Claudia
Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
J Clin Med. 2024 Apr 24;13(9):2494. doi: 10.3390/jcm13092494.
BACKGROUND/OBJECTIVES: Depression is a prevalent and debilitating illness that significantly affects psychological and physical well-being. Apart from conventional therapies such as psychotherapy and medication, individuals with depression often lack opportunities for activities that are generally perceived as enjoyable, such as music, meditation, and arts, which have demonstrated therapeutic effectiveness. TaKeTiNa music therapy has been employed as a therapeutic intervention for more than two decades. However, there is a notable absence of well-designed clinical trials investigating its antidepressant effects, a gap we aim to address in our current study. Furthermore, shifts in the progression of depression may manifest both psychologically, by influencing emotional states, and physiologically, by leading to alterations in lipid and sphingolipid metabolism, cortisol levels, and immune system function. Our study seeks to analyze the impact of TaKeTiNa music therapy on both levels.
This is a prospective monocentric randomized waitlist-controlled clinical trial. It investigates the influence of TaKeTiNa music therapy on patients with major depression in an outpatient setting. Therefore, interested persons are randomly assigned to two groups, an intervention group or a control group, after completing a screening procedure. The intervention group starts with an eight-week TaKeTiNa music therapy intervention. The waiting group receives the same therapy program after completing the follow-up period. Blood and saliva sampling as well as responses to questionnaires are obtained at specific time points.
Our study investigates the effects of TaKeTiNa music therapy, a non-pharmacological antidepressant treatment option, on depressive symptoms. We also address functional and causal immunological changes; hormonal changes, such as changes in cortisol levels; and metabolic changes, such as changes in serum lipids and sphingolipids, during the course of depression. We expect that this study will provide evidence to expand the range of treatment options available for depression.
背景/目的：抑郁症是一种常见且使人衰弱的疾病，会显著影响心理和身体健康。除了心理治疗和药物治疗等传统疗法外，抑郁症患者通常缺乏参与一般被认为有趣的活动的机会，如音乐、冥想和艺术活动，而这些活动已被证明具有治疗效果。塔科蒂纳音乐疗法作为一种治疗干预手段已应用了二十多年。然而，目前明显缺乏精心设计的临床试验来研究其抗抑郁效果，我们旨在通过当前的研究填补这一空白。此外，抑郁症进展过程中的变化可能在心理层面通过影响情绪状态表现出来，在生理层面则通过导致脂质和鞘脂代谢、皮质醇水平及免疫系统功能的改变而体现。我们的研究旨在分析塔科蒂纳音乐疗法在这两个层面上的影响。
这是一项前瞻性单中心随机等待列表对照临床试验。该试验在门诊环境中研究塔科蒂纳音乐疗法对重度抑郁症患者的影响。因此，感兴趣的人在完成筛查程序后被随机分为两组，即干预组和对照组。干预组开始为期八周的塔科蒂纳音乐疗法干预。等待组在完成随访期后接受相同的治疗方案。在特定时间点采集血液和唾液样本并获取问卷回复。
我们的研究调查了塔科蒂纳音乐疗法（一种非药物抗抑郁治疗选择）对抑郁症状的影响。我们还探讨了抑郁症病程中功能和因果性免疫变化、激素变化（如皮质醇水平变化）以及代谢变化（如血清脂质和鞘脂变化）。我们期望这项研究将为扩大抑郁症的治疗选择范围提供证据。
